Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands.
As Europe’s leading forum for drug safety and pharmacovigilance, the congress provides an important platform to exchange knowledge and address the most pressing challenges faced by safety professionals.
At Aurealis Therapeutics, patient safety is central to everything we do. With our completed Phase 2 DFU “DIAMEND” study and initial preparations for our upcoming DFU pivotal study, participation in leading forums such as this helps us strengthen our expertise and uphold the highest standards in patient safety and pharmacovigilance.